Bioana is officially ISO 13485 certified!
Learn more →
You built a prototype. It works. Your team has tested it, refined it, and validated the concept. But here's a question that many MedTech founders and engineering teams encounter later than they'd like:
Does a working prototype mean your device is actually ready for manufacturing? The answer, more often than not, is: not yet.
This guide is designed to help you understand what manufacturing readiness actually involves, and how to evaluate where your device stands before committing to production.
The gap that matters
A prototype is designed to prove a concept. A manufacturable product is designed to be built consistently, at scale, within cost, and in full compliance with regulatory requirements.
A prototype can tolerate hand-finishing, one-off adjustments, and manual workarounds. Production cannot.
What works in a controlled R&D environment may not hold up when you're building 500 or 5,000 units with consistent dimensional tolerances, validated materials, and documented processes that regulators can audit.
Self-assessment
Before moving into production planning, evaluate your device against these common indicators.
Design for Manufacturing (DFM) is the process of evaluating and refining a device design so it can be produced reliably, consistently, and cost-effectively at scale. It's not a checklist, it's a structured conversation between engineering, manufacturing, and regulatory teams that should begin as early as concept development. If your device has been developed primarily by an engineering team without formal manufacturing input, a DFM review is a critical next step before advancing.
Complex manual assembly might be manageable in a prototype setting, but it creates significant challenges at production scale. Inconsistency in manual steps can lead to quality variability, higher scrap rates, and difficulties during process validation, all of which can delay regulatory submissions and increase costs. Evaluating your device for Design for Assembly (DFA) alongside DFM is an important part of manufacturing readiness.
A device that depends on single-source suppliers, long-lead-time components, or specialty materials that aren't readily available in production quantities may face supply chain risks that don't become visible until you're trying to scale. Supplier qualification under ISO 13485 is a documented, auditable process, not just a procurement decision. Identifying and qualifying suppliers early, during the design phase rather than after it, can meaningfully reduce the risk of design changes driven by component availability.
Manufacturing a regulated medical device requires a Design History File (DHF) that documents the development process systematically. If your development history lives in email threads, informal notes, or undocumented engineering decisions, that gap will need to be addressed before you can move into a compliant manufacturing process. The earlier this documentation is structured, the lower the cost of organizing it.
Frequent design iterations late in development are often a signal that manufacturing constraints haven't been fully surfaced or resolved. While iteration is a normal part of development, design changes after a formal design freeze can be significantly more expensive and time-consuming than changes made earlier.
Before you scale
Here are the key areas to assess:
Evaluates your device against production requirements: tolerances, materials, assembly processes, and quality control checkpoints. Identifies gaps between the current design and consistent, scalable production.
V&V testing should be planned in parallel with manufacturing preparation, not after it. Devices designed without production constraints in mind may struggle to achieve stable operating windows during validation.
Low-volume pilot builds are one of the most effective tools for identifying manufacturing issues before committing to full production executed under production-representative conditions, using the same processes, materials, and documentation.
A production BOM (Bill of Materials) should reflect components that are available, qualifiable, and cost-appropriate at your target volume. A BOM review early in manufacturing preparation can identify substitutions that improve availability, reduce lead times or lower unit cost without compromising compliance.
Not all suppliers are qualified to support regulated medical device manufacturing. Evaluating your supply chain in accordance with ISO 13485 requirements, including supplier audits, quality agreements, and incoming inspection protocols is a foundational step in manufacturing preparation.
Early vs. late action
Late-stage design changes are expensive and can add months and significant cost to a development program.
More importantly, they're largely avoidable when manufacturing readiness is treated as a parallel workstream to engineering development, not as something that comes after the design is "done."
MedTech companies that integrate manufacturing expertise early tend to reach design freeze with fewer surprises, move through V&V more efficiently, and encounter fewer issues during regulatory review. The investment in manufacturing readiness upfront is consistently less costly than the remediation required when problems are discovered late.
How Bioana supports
Bioana works with MedTech companies across the full development cycle, from early concept and low-volume prototype production through Verification and Validation Testing, FDA Clearance and Approval, and Contract Manufacturing.
Our integrated approach means that manufacturing considerations are part of the design conversation from day one, not introduced as a constraint after the design is finalized.
If your device is approaching the transition from development to production, or if you're not sure where you stand, a manufacturing readiness assesment can help clarify the path forward.
Our team can help you assess your device's manufacturing readiness and identify the right next steps.
Talk to a Bioana expert →
“Bioana team, you guys are simply amazing. Thanks so much for all your team’s hard work on this. We remain impressed beyond measure.”
Mark Lee
CEO, Ocumetics
"Our experience with Bioana had been outstanding. Their commitment, eye for detail, punctuality, proactivity and understanding manufacturing principles, workflow, quality and resourcefulness has been beyond our expectations."
Frank Harder
CRO , Bolb Inc.
.jpg)
.jpg)
.jpg)
.jpg)
